RT Journal Article
SR Electronic
T1 Tissue-specific enhancer-gene maps from multimodal single-cell data identify causal disease alleles
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.27.22281574
DO 10.1101/2022.10.27.22281574
A1 Sakaue, Saori
A1 Weinand, Kathryn
A1 Isaac, Shakson
A1 Dey, Kushal K.
A1 Jagadeesh, Karthik
A1 Kanai, Masahiro
A1 Watts, Gerald F. M.
A1 Zhu, Zhu
A1 ,
A1 Brenner, Michael B.
A1 McDavid, Andrew
A1 Donlin, Laura T.
A1 Wei, Kevin
A1 Price, Alkes L.
A1 Raychaudhuri, Soumya
YR 2023
UL http://medrxiv.org/content/early/2023/03/08/2022.10.27.22281574.abstract
AB Translating genome-wide association study (GWAS) loci into causal variants and genes requires accurate cell-type-specific enhancer-gene maps from disease-relevant tissues. Building enhancer-gene maps is essential but challenging with current experimental methods in primary human tissues. We developed a new non-parametric statistical method, SCENT (Single-Cell ENhancer Target gene mapping) which models association between enhancer chromatin accessibility and gene expression in single-cell multimodal RNA-seq and ATAC-seq data. We applied SCENT to 9 multimodal datasets including > 120,000 single cells and created 23 cell-type-specific enhancer-gene maps. These maps were highly enriched for causal variants in eQTLs and GWAS for 1,143 diseases and traits. We identified likely causal genes for both common and rare diseases. In addition, we were able to link somatic mutation hotspots to target genes. We demonstrate that application of SCENT to multimodal data from disease-relevant human tissue enables the scalable construction of accurate cell-type-specific enhancer-gene maps, essential for defining non-coding variant function.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported in part by funding from the National Institutes of Health (R01AR063759, U01HG012009, UC2AR081023).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study used samples collected underIRB approved protocols at Brigham and Women's Hospital and Hospital for Special Surgery.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors